Drotrecogin alfa (activated) (LY203638) exploratory, safety study, multi-center, randomized, placebo-controlled, dose escalating study design, comparing a standard therapy (enoxaparin sodium) for submassive pulmonary embolism to a combined therapy of drotrecogin alfa (activated) plus enoxaparin sodium.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2009
At a glance
- Drugs Drotrecogin alfa; Enoxaparin sodium
- Indications Pulmonary embolism
- Focus Adverse reactions
- 14 May 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 05 Nov 2005 New trial record.